Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Debbie M. Jakubowski"'
Autor:
Henry L. Gomez, Juan E. Bargallo-Rocha, Roberto J. Billinghurst, Aníbal R. Núñez De Pierro, Federico A. Coló, Lisandro L. B. Gil, Carola Allemand, Ignacio L. McLean, Mauricio Lema-Medina, Fernando Herazo-Maya, Francisco J. Terrier, Raquel G. Cwilich, Mauricio Leon, Silvia G. Falcon, Roberto E. Castaño, Sergio C. Oliveira, Debbie M. Jakubowski, Calvin Chao
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 1364-1373 (2021)
PURPOSEWe present a physician survey of the impact of 21-gene Breast Recurrence Score test results on treatment decisions in clinical practice in Latin America.METHODSThis prospective survey enrolled consecutive patients at 14 sites in Argentina, Col
Externí odkaz:
https://doaj.org/article/d419e7ed949e4df185a1e6c2f84e999c
Autor:
André Mattar, Guilherme R. Fonseca, Murilo B. A. Romão, Jorge Y. Shida, Vilmar M. de Oliveira, Maria C. S. Bastos, Fabio Bagnoli, Jose F. Rinaldi, Monica M. Á. Stiepcich, Maria A. L. G. da Silva, Debbie M. Jakubowski, Calvin Chao, Sergio C. Oliveira, Luiz H. Gebrim
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 1003-1011 (2021)
PURPOSEWe evaluated the impact of 21-gene test results on treatment decisions for patients with early-stage breast cancer treated under the public health care system in Brazil, Sistema Único de Saúde.METHODSEligible patients treated at Hospital Pé
Externí odkaz:
https://doaj.org/article/3bf8a39fc7094683939444319dace9c1
Autor:
Debbie M Jakubowski, Mauricio Lema-Medina, Juan Enrique Bargallo-Rocha, Fernando Herazo-Maya, Lisandro Luis Benitez Gil, Federico Coló, Carola Allemand, Henry L. Gomez, Mauricio Leon, Roberto Jorge Billinghurst, Raquel Gerson Cwilich, Francisco Jose Terrier, Ignacio Leonardo McLean, Calvin Chao, Sergio C Oliveira, Silvia Falcon, Aníbal Roberto Núñez de Pierro, Roberto Eduardo Castaño
Publikováno v:
JCO Global Oncology
PURPOSEWe present a physician survey of the impact of 21-gene Breast Recurrence Score test results on treatment decisions in clinical practice in Latin America.METHODSThis prospective survey enrolled consecutive patients at 14 sites in Argentina, Col
Autor:
Tal Sella, Kathryn J. Ruddy, Eric P. Winer, Yaileen D Guzman-Arocho, Rulla M. Tamimi, Debbie M Jakubowski, Lidia Schapira, Ellen Warner, Laura C. Collins, Philip D. Poorvu, Shari Gelber, Jeffrey Peppercorn, Shoshana M. Rosenberg, Ann H. Partridge, Steven E. Come, Christy A. Russell, Laura S. Dominici, Virginia F. Borges, Hee Jeong Kim, Craig Snow
Publikováno v:
Breast Cancer Research and Treatment. 186:157-165
The 21-gene Breast Recurrence Score test predicts benefit from adjuvant chemotherapy in estrogen receptor-positive, HER2-negative (ER+/HER2−) breast cancer (BC). We examined whether the 21-gene assay predicts response to neoadjuvant chemotherapy (N
Autor:
Frederick L. Baehner, Andrea Blacklock, John Abran, Vivian Tan, Helen Bailey, Rebekah Young, Debbie M Jakubowski, Carolyn Mies, Anna Lau, Nancy Ciau
Publikováno v:
Journal of Surgical Oncology
Background and Objective Recent COVID‐19 pandemic guidelines recommend genomic assessment of core biopsies to help guide treatment decisions in estrogen receptor (ER)‐positive early‐stage breast cancer. Herein we characterize biopsy and excisio
Publikováno v:
Cancer Research. 80:P3-07
Introduction: The 21-gene Breast Recurrence Score® assay was shown in SWOG 8814 to predict chemotherapy (CT) benefit for patients (pts) with N+ BC and Recurrence Score® (RS) result≥31 but not RS 5-year BCSM, by RS Group and Reported CT UseCT repo
Autor:
EP Winer, S Shak, KS Albain, Gabriel N. Hortobagyi, GW Sledge, Valentina I. Petkov, Norman Wolmark, Debbie M Jakubowski, Eleftherios P. Mamounas
Publikováno v:
Cancer Research. 79:P3-11
Introduction: The 21-gene Breast Recurrence Score® (RS) in the randomized NSABP B-20, SWOG S8814, and TAILORx studies predicted chemotherapy (CT) benefit for pts with N0 and N+ disease. Endocrine therapy was not inferior to chemoendocrine therapy in
Autor:
Ellen Warner, Laura C. Collins, Virginia F. Borges, Rulla M. Tamimi, Christy A. Russell, S Come, Shari Gelber, Philip D. Poorvu, Jeffrey Peppercorn, AH Partridge, Shoshana M. Rosenberg, Kathryn J. Ruddy, Lidia Schapira, Debbie M Jakubowski, EP Winer
Publikováno v:
Cancer Research. 79:P2-08
Background: The 21-gene Recurrence Score (RS) assay is prognostic among women with early-stage estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) and is used to select patients for chemothe
Autor:
Peter J. Mazzone, Kyle Work, Victor E. Velculescu, Sonali Kotagiri, Lee Ming Sun, Daniel Dix, Debbie M Jakubowski, Alessandro Leal, Peter Brian Bach, Tara Maddala
Publikováno v:
Journal of Clinical Oncology. 40:TPS3164-TPS3164
TPS3164 Background: Despite longstanding national recommendations, uptake of lung cancer screening in the US remains low. Barriers include access to lung cancer screening, costs, and concerns over potential harms like false-positives and radiation ex
Autor:
Ellen Warner, Laura C. Collins, Shari Gelber, Ann H. Partridge, Lidia Schapira, Debbie M Jakubowski, Jeffrey Peppercorn, Shoshana M. Rosenberg, Virginia F. Borges, Kathryn J. Ruddy, Eric P. Winer, Christy A. Russell, Steven E. Come, Rulla M. Tamimi, Philip D. Poorvu
Publikováno v:
Journal of Clinical Oncology
PURPOSE The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor–positive (ER+) and human epidermal growth factor receptor 2–negative (HER2−) breast cancer and is used to inform recommendations for ch